NCT05309187 - Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

March 29, 2024

Study Completion Date

May 31, 2024

Conditions

Solid Tumor, Adult

Interventions

BIOLOGICAL

IO-202

IO-202 given as monotherapy

BIOLOGICAL

IO-202 + pembrolizumab combination therapy

IO-202 and fixed dose pembrolizumab combination therapy

BIOLOGICAL

RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types

Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.

Trial Locations (10)

Tisch Mount Sinai (124), New York

NEXT Oncology Virginia (121), Fairfax

Carolina BioOncology (102), Huntsville

Sarah Cannon Research Institute/Tennessee Oncology (122), Nashville

Indiana University (123), Indianapolis

Northwestern University - Feinberg School of Medicine (133), Chicago

Mary Crowley Cancer Research (108), Dallas

MD Anderson Cancer Center (101), Houston

USC-Norris Comprehensive Cancer Center (119), Los Angeles

University of Florida (125), Gainesville